Lenacapavir is a new type of HIV medicine that blocks the virus’s capsid, a protein shell that protects the virus’s genetic material. In this study it is given as a pill or injection twice a year to see if it can keep the virus suppressed when used with other drugs.
Teropavimab is a broadly neutralizing antibody that is given by IV infusion. It works by attaching to HIV and preventing it from infecting cells. The trial tests whether adding this antibody to the regimen helps maintain viral suppression.
Zinlirvimab is another broadly neutralizing antibody administered by IV infusion. Like teropavimab, it targets HIV directly and blocks the virus from entering cells. The study evaluates its combined effect with lenacapavir and teropavimab.
Cobicistat is a booster medication that increases the levels of other HIV drugs in the body. In the trial participants who stay on their usual oral regimen continue to take cobicistat as part of their combination therapy.
Dolutegravir is an integrase inhibitor that stops HIV from inserting its genetic material into human cells. It is one of the standard drugs used by participants who remain on their usual oral treatment.
Etravirine belongs to a class called non‑nucleoside reverse transcriptase inhibitors (NNRTIs). It blocks an enzyme the virus needs to make copies of its RNA. Participants on the standard regimen may be taking etravirine.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the virus’s ability to copy its genetic code. It is a common component of many oral HIV treatment combos in the study.
Raltegravir is another integrase inhibitor that prevents HIV from integrating its DNA into the host’s cells. It is part of the oral regimen for some participants who do not switch to the new antibodies.
Efavirenz is an NNRTI that blocks an enzyme needed for viral replication. It is included in the standard oral therapy for certain participants.
Atazanavir is a protease inhibitor that stops the virus from maturing into a form that can infect new cells. It is used by participants who continue their usual oral regimen.
Rilpivirine is an NNRTI taken orally to inhibit HIV replication. It is part of the existing treatment for some study participants.
Abacavir is an NRTI that interferes with the virus’s ability to make DNA. It is included in the oral treatment options for participants who remain on their current regimen.
Doravirine is an NNRTI that blocks HIV’s reverse transcriptase enzyme. It is one of the drugs participants may continue taking in the standard oral therapy.
Ritonavir is a protease inhibitor that is also used to boost the levels of other HIV drugs. In the study it remains part of the oral regimen for participants who do not switch.
Lamivudine is an NRTI that stops HIV from copying its genetic material. It is commonly combined with other drugs in the standard oral regimen.
Tenofovir alafenamide is a newer form of tenofovir that enters cells and blocks viral replication. It is included in combination pills that participants may continue using.
Elvitegravir is an integrase inhibitor that prevents HIV from integrating its DNA into host cells. It is part of some fixed‑dose combination tablets used by participants staying on oral therapy.
Darunavir is a protease inhibitor that stops HIV from maturing. It is taken by participants who remain on their existing oral regimen.
Tipranavir is a protease inhibitor used in combination with other drugs to control HIV. It is part of the oral treatment options for participants who do not switch to the new regimen.
Tenofovir disoproxil is an older form of tenofovir that blocks HIV replication. It is included in some of the standard oral combination pills used by participants who stay on their usual therapy.
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands